AndroGel Update: Jury Orders AbbVie to Pay Over $3 Million
A federal jury in Illinois awarded over $3 million to Jesse Mitchell in a bellwether retrial involving AndroGel testosterone therapy. This is the fourth bellwether trial against AbbVie and the third time AbbVie has been penalized with punitive damages for AndroGel.
The jury found AbbVie Inc.’s AndroGel product to be the cause of Mitchell’s heart attack. They ordered the company pay him $200,000 in compensatory damages — $150,000 for economic damages — and $3 million in punitive damages. The jury found AbbVie to be negligent; Plaintiffs argued that AbbVie ignored signs that AndroGel increased the risk of heart attacks or other blood clotting issues.
Thousands of individuals in the MDL are claiming AbbVie marketed the testosterone replacement therapy to aging men without testing for safety and efficacy. Mitchell claimed AbbVie promoted the therapy drug to men like him without FDA approval. Mitchell was not diagnosed with a specific condition that caused his low testosterone levels.
AbbVie faces thousands of lawsuits that are pending in the MDL. More trials are scheduled. Hopefully, this will ultimately lead to settlement of these cases.
GoldenbergLaw has been very active in this litigation. We are continuing to accept AndroGel testosterone therapy drug cases.